Advertisement
Organisation › Details
Acacia Pharma (Group)
Acacia Pharma is a hospital pharmaceutical group focused on the development and commercialisation of new nausea & vomiting treatments for surgical and cancer patients. The Group has identified important and commercially attractive unmet needs in nausea & vomiting and has discovered two product candidates based on the same active ingredient, amisulpride, to meet those needs. The Group’s lead project, BAREMSIS for post-operative nausea & vomiting (PONV), has generated positive results in Phase 3 clinical studies and an NDA has been accepted for filing by the US FDA for marketing approval. Its sister project, APD403 for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy. Acacia Pharma is based in Cambridge, UK and its US operations are centred in Indianapolis, IN. *
Start | 2010-10-23 existent | |
Today | Acacia Pharma Ltd. | |
Industry | Baremsis (APD421) | |
Industry 2 | APD403 (Acacia Pharma) | |
Person | Gilbert, Julian C. (Acacia Pharma Ltd 201309 CEO + Co-Founder) | |
Person 2 | Soden, Christine (Acacia Pharma 201507– CFO joined 201502 before Celltech-Chiroscience + BTG + Optos + Medeva + Oxagen) | |
Region | Harston, Cambridgeshire | |
Country | United Kingdom (GB) | |
Street | Harston Mill | |
City | CB22 7GG Harston, Cambridgeshire | |
Tel | +44-1223-875130 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | A: 1 to 10 (2018-03-02) |
Currency | GBP | |
Profit | -6,172,000 (2017-12-31) | |
Cash | 3,070,000 (2017-12-31) | |
* Document for »About Section«: | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Acacia Pharma (Group)
- [1] Paion AG. (7/2/20). "Press Release: Paion Announces U.S. FDA Approval of Remimazolam (Byfavo) for the Induction and Maintenance of Procedural Sedation". Aachen....
- [2] Euronext N.V.. (3/5/18). "Press Release: Acacia Pharma Lists on Euronext Brussels". Brussels....
- [3] Acacia Pharma Group Ltd.. (3/2/18). "Press Release: Acacia Pharma Successfully Prices Initial Global Offering at EUR 3.60 per Share Raising EUR40m [Not for US, AU, CA, JP, ZA, et al.]". Cambridge & Indianapolis, IN....
- [4] Acacia Pharma Group Ltd.. (2/5/18). "Press Release: Acacia Pharma Announces Its Intention to Launch an Initial Global Offering and to List Its Shares on Euronext Brussels [Not for US, AU, CA, JP, ZA, et al.]". Cambridge & Indianapolis, IN....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top